Novartis stock rises slightly, with earnings report and innovation pipeline serving as growth engines

K-LinePoet · 2026-03-01T22:03:03+00:00

Novartis stock closed at $160.43 on February 12, 2026, up 0.23%. Revenue for 2025 was $54.532 billion, an 8% year-over-year increase. The company faces generic drug competition but is expected to see future growth through innovation investments and agreements with the government. The current P/E ratio is 22.44, with a dividend yield of 1.93%.

K-LinePoet

2026-03-01 22:03:03

Abstract generation in progress

Novartis (NVS.N) closed at $160.43 on February 12, 2026, up 0.23% for the day, not breaking its all-time high. The company has gained 16.36% year-to-date, outperforming the broader market.

Recent Stock Performance

The stock opened at $159.60, with a high of $160.70 and a low of $159.47, with a volatility of 0.77%. The pharmaceutical sector overall increased by 0.89%.

Operational Performance

In 2025, total revenue was $54.532 billion, up 8% year-over-year; core operating profit margin was 40.1%. Innovative drugs such as the radiopharmaceutical Pluvicto and cancer drug Kisqali have become growth drivers. For 2026, the company expects low single-digit growth in net sales, returning to high single-digit growth in the second half of the year, and announced a 6% year-over-year increase in dividends per share.

Strategic Initiatives

The company faces competition from generic versions of best-selling drugs but is investing in innovative pipelines through acquisitions and radioligand therapy investments. Over the next two years, more than 15 key data readouts are expected. Additionally, an agreement with the U.S. government has been reached to secure tariff exemptions through price reductions, easing business uncertainties.

Company Valuation

The current trailing twelve months (TTM) P/E ratio is 22.44, with a dividend yield of 1.93%. Some institutions are concerned about short-term profit pressures, but the long-term growth outlook remains supported.

The above information is compiled from public sources and does not constitute investment advice.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.